Drugs / CD19/CD20 Tandem Dual CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07546630 | Apr 2026 → May 2028 expected | B-cell non-Hodgkin lymphoma | Affiliated Hospital to Academy of Military Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD20 Tandem Dual CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07546630 ↗ |
| Modality | Cell therapy | “Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy” NCT07546630 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT07546630 ↗ |